MedTrace Logo

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

NCT01006291 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 687

Last updated 2017-02-09

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes. Subjects treated with oral antidiabetic drug(s) (OAD(s)) should continue their current OAD treatment at the stable, prerandomisation dose level and dosing frequency.

Conditions

Interventions

DRUG

insulin degludec

Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.

DRUG

insulin degludec

Injected s.c. (under the skin) once daily. Dose was individually adjusted.

DRUG

insulin glargine

Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Argentina
  • Finland
  • Hungary
  • India
  • Israel
  • Malaysia
  • Mexico
  • North Macedonia
  • Norway
  • Russia
  • Serbia
  • South Africa
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006291 on ClinicalTrials.gov